炎症性肠病深度缓解后停用硫唑嘌呤的无创监测
粪便钙卫蛋白是唯一与复发显著相关的变量,其阳性对复发具有高特异性,可用于早期调整治疗策略。
要点
- 深度缓解后停用硫唑嘌呤,溃疡性结肠炎复发率高于克罗恩病。
- 粪便钙卫蛋白阳性与两种疾病复发高风险独立相关。
- 定期监测粪便钙卫蛋白有助于早期发现复发并调整治疗。
核心结论
- 超过半数溃疡性结肠炎和三分之一克罗恩病患者在深度缓解后停用硫唑嘌呤仍会复发。
- 粪便钙卫蛋白阳性与复发高风险相关,可帮助早期纠正治疗策略。
研究设计与样本
- 停用硫唑嘌呤中位时间7年(范围5-19),随访中位50个月(范围25-85)。
主要发现
- 26例患者复发(溃疡性结肠炎18/31,克罗恩病8/26;P = .003),中位复发时间15个月(范围2-37)。
- 粪便钙卫蛋白是唯一与两种疾病后续复发显著相关的变量(溃疡性结肠炎:风险比3.3;95%置信区间1.2-10;克罗恩病:风险比4.5;95%置信区间1.4-12.5)。
- 粪便钙卫蛋白的敏感性、特异性、阳性预测值和阴性预测值在溃疡性结肠炎分别为50%、100%、100%和59%,在克罗恩病分别为50%、94%、80%和81%。
临床怎么用
- 对深度缓解后停用硫唑嘌呤的炎症性肠病患者,可定期监测粪便钙卫蛋白。
- 粪便钙卫蛋白阳性提示复发高风险,应考虑早期调整治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is uncertainty regarding the optimal duration of treatment with azathioprine (AZA) in ulcerative colitis (UC) and Crohn's disease (CD). We analyzed the clinical course and predictors of relapse after AZA withdrawal in patients in sustained deep remission. METHODS: A prospective study was performed on patients who stopped their treatment with AZA while being in steroid-free, extended deep remission (normal clinical, endoscopic, and histologic indexes, C-reactive protein, and fecal calprotectin [FC]). Standard biochemical tests and FC were measured at 3 and 6 months, then every 6 months. Bowel ultrasounds and ileocolonoscopy were performed every 6 and 12 months, respectively. Multivariate analysis for predictors of relapse was performed using a Cox proportional hazards model and hazard ratios were calculated. Spearman nonparametric correlation test was also used. The accuracy of significant predictors was calculated. RESULTS: Fifty-seven patients with inflammatory bowel disease stopped AZA after median 7 years (range, 5-19) and were followed up for median 50 months (range, 25-85). Twenty-six patients (18/31 UC, 8/26 CD; P = .003) relapsed, within a median 15 months (range, 2-37). FC was the only variable significantly correlated with later relapse of both diseases (UC: hazard ratio, 3.3; 95% confidence interval, 1.2-10; CD: hazard ratio, 4.5; 95% confidence interval, 1.4-12.5). The sensitivity, specificity, and positive and negative predictive values of FC were 50%, 100%, 100%, and 59% in UC and 50%, 94%, 80%, and 81% in CD. CONCLUSIONS: More than half patients with UC and one-third of patients with CD relapse after AZA withdrawal despite previous deep remission. FC positivity is associated with high risk of relapse, allowing early correction of the therapeutic strategy.
引用
- Cassinotti A, Corona A, Duca P, et al. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. Clin Gastroenterol Hepatol. 2021. PMID: 34139332. doi:10.1016/j.cgh.2021.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。